Vasopressin as Possible Treatment Option in Autism Spectrum Disorder

Area of Science:

• Neuroscience
• Endocrinology
• Developmental Psychology

Background:

• Autism spectrum disorder (ASD) is characterized by social communication deficits and repetitive behaviors.
• The neuropeptide vasopressin is involved in social behavior, stress regulation, and homeostasis.
• Emerging evidence suggests a potential link between vasopressin and the pathophysiology of ASD.

Purpose of the Study:

• To review the multifaceted role of vasopressin in the development and presentation of ASD.
• To explore the anatomical and functional connections between the vasopressinergic system and ASD-related symptoms.
• To evaluate vasopressin as a potential therapeutic target for ASD.

Main Methods:

• Comprehensive literature review of studies investigating vasopressin and ASD.
• Analysis of functional and anatomical data linking vasopressin pathways to ASD.
• Examination of clinical trial outcomes for vasopressin-based interventions.

Main Results:

• Vasopressin may influence social skills, communication, motor function, autonomic regulation, sleep, and sensory processing in ASD.
• Key brain regions involved in ASD and vasopressin signaling include the hypothalamus, amygdala, and hippocampus.
• Sex differences in the vasopressinergic system may contribute to the higher prevalence of ASD in males.
• Clinical trials show mixed but promising results for vasopressin and V1a receptor antagonists in ASD.

Conclusions:

• Vasopressin is a compelling candidate for ASD treatment, potentially benefiting specific subgroups, particularly males.
• Further research is needed to elucidate the precise mechanisms and optimize targeted delivery strategies for vasopressin-based therapies.
• Interventions targeting the vasopressinergic system, including V1a receptor antagonists, warrant continued investigation for ASD management.